Comparison of arthritis with PLV-LMCs showed no relationship between severity (Placebo, R2 = 0.09/R2 = 0.13), recovery (anti-TNF, R2 = 0.04/R2 = 0.29), or combined treatment effects (All, R2 = 0.09/R2 = 0.03) of talus bone erosions/tarsal synovitis and αSMA+ PLV-LMC coverage (Figs. 3A,B). The gene discussed is TNF; the disease is Arthritis.